Journal of Thoracic Oncology

The survival benefit first reported in 2023 has held five years after the last dose of adjuvant osimertinib, which answers the worry that a three-year course only delays relapse. Patients with an exon 19 deletion gained most; the L858R estimate crosses one and is less certain. Nothing here changes the recommendation, which already rests on the 2023 analysis, but it tightens the case for testing every resected non-squamous tumour for EGFR mutations.

This is the paper Europe PMC returns for registry id NCT06015503 with the most citations, so it is the natural first reading for anyone following the KANNON trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT05955391 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT05186974 with the most citations, so it is the natural first reading for anyone following the EVOKE-02 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT04665856 with the most citations, so it is the natural first reading for anyone following the SKYSCRAPER-02C trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT05168566 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT03003962 with the most citations, so it is the natural first reading for anyone following the PEARL trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT06120140 with the most citations, so it is the natural first reading for anyone following the COCOON trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT04644237 with the most citations, so it is the natural first reading for anyone following the DESTINY-Lung02 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT05663866 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

A second publication from the RELAY trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT03915951 with the most citations, so it is the natural first reading for anyone following the PHAROS trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

One treatment page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

A second publication from the CameL trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT03381274 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

One treatment page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT03775486 with the most citations, so it is the natural first reading for anyone following the ORION trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

It corrected a widely repeated simplification. An STK11 or KEAP1 mutation is not by itself a reason to expect immunotherapy to fail; it is a reason to expect it in a KRAS-mutant tumour, which is how the result should be read on a report.

The names on a thymic pathology report, and the sharp line between thymoma and thymic carcinoma that drives treatment, come from this classification.

One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT03607539 with the most citations, so it is the natural first reading for anyone following the ORIENT-11 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

It is the reality check on the subtype model and it has a direct consequence for treatment: the DLL3-directed medicines are aimed at the neuroendocrine-high subtypes, and the POU2F3 and double-negative tumours will not express the target.

It gives the sequencing report a prognostic reading that does not depend on a repeat biopsy: an EGFR-mutant cancer that also carries RB1 and TP53 alterations will stop responding sooner and should be watched for a change of histology.

This is the paper Europe PMC returns for registry id NCT02154490 with the most citations, so it is the natural first reading for anyone following the Lung-MAP trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

It is the reason a laboratory can run one stain and report against several drug labels, and the reason any decision resting on an immune-cell score rests on the least reproducible number in lung pathology.

It is the document that defines what a complete lung cancer molecular report looks like, and its asymmetry about plasma, rule in but never rule out, is the single most useful sentence in it.

Two bottleneck pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

The survival benefit first reported in 2023 has held five years after the last dose of adjuvant osimertinib, which answers the worry that a three-year course only delays relapse. Patients with an exon 19 deletion gained most; the L858R estimate crosses one and is less certain. Nothing here changes the recommendation, which already rests on the 2023 analysis, but it tightens the case for testing every resected non-squamous tumour for EGFR mutations.

This is the paper Europe PMC returns for registry id NCT06015503 with the most citations, so it is the natural first reading for anyone following the KANNON trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT05955391 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT05186974 with the most citations, so it is the natural first reading for anyone following the EVOKE-02 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT04665856 with the most citations, so it is the natural first reading for anyone following the SKYSCRAPER-02C trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT05168566 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT03003962 with the most citations, so it is the natural first reading for anyone following the PEARL trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.

This is the paper Europe PMC returns for registry id NCT06120140 with the most citations, so it is the natural first reading for anyone following the COCOON trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.